Skip to main content
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 5.86
Day High 6.00
Open:5.92
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not currently operate in the U.S. due to federal prohibition. The company is focusing on expanding through international cultivation and distribution into the global medical cannabis market. Aphria also offers multiple products under a portfolio of recreational cannabis brands, including Solei, RIFF, and Broken Coast.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Meta Growth Shareholders Overwhelmingly Approve Transformational Business Combination with High Tide to Create Canada's Largest Cannabis Retailer
- CNW Group - Wed Oct 28, 6:00AM CDT
CNW Group - CMTX
Wed Oct 28, 6:00AM CDT
Meta Growth Shareholders Overwhelmingly Approve Transformational Business Combination with High Tide to Create Canada's Largest Cannabis Retailer
Association with Medical Applications Helps Drive Cannabis' Expansion
- PR Newswire - PRF - Thu Oct 22, 8:00AM CDT
PR Newswire - PRF - CMTX
Thu Oct 22, 8:00AM CDT
, /PRNewswire/ -- Cannabidiol-based (CBD) products' attribution to various medical applications has prompted a rapid emergence of new products. Yet, despite the increase in popularity, the FDA has only approved one cannabis-based drug, Epidolex, which is used to treat epilepsy. Nevertheless, thousands of retailers and e-commerce platforms begun to sell CBD products after the passage of the U.S. Farm Bill in 2018. And the remarkable progress the CBD industry has made in the past several years highlights that the cannabis compound has the potential to become the next up and coming medication or even simply a health and wellness product. And, according to a research report, The U.S. Cannabis Report: 2020-2021 Industry Outlook, published by New Frontier Date, the total combined legal sales of medical and adult-use cannabis in the U.S. are projected to reach by 2025. MediPharm Labs Corp. (OTC: MEDIF) (TSX: LABS), Aphria Inc. (NASDAQ: APHA) (TSX: APHA), HEXO Corp. (NYSE: HEXO), Organigram Holdings Inc. (NASDAQ: OGI), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) 
Aphria Inc. Announces Record Adult-Use Cannabis Gross Revenue in First Quarter Fiscal Year 2021 and Sixth Consecutive Quarter of Positive Adjusted EBITDA
- CNW Group - Thu Oct 15, 7:00AM CDT
CNW Group - CMTX
Thu Oct 15, 7:00AM CDT
Aphria Inc. Announces Record Adult-Use Cannabis Gross Revenue in First Quarter Fiscal Year 2021 and Sixth Consecutive Quarter of Positive Adjusted EBITDA
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 5.70 +4.56% increase
on 10/02/20
Period Open:5.80
Price movement based on the high, low and last over the given period.
8.29 -28.11% decrease
on 10/13/20
+0.16 (+2.76%) increase
since 09/29/20
3-Month 5.58 +6.81% increase
on 09/25/20
Period Open:6.52
Price movement based on the high, low and last over the given period.
8.29 -28.11% decrease
on 10/13/20
-0.56 (-8.59%) decrease
since 07/29/20
52-Week 2.65 +124.91% increase
on 03/16/20
Period Open:6.59
Price movement based on the high, low and last over the given period.
8.29 -28.11% decrease
on 10/13/20
-0.63 (-9.56%) decrease
since 10/29/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies